Company Encyclopedia
View More
name
Bayer
BAYRY.US
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health.
4.496 T
BAYRY.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking122/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-0.66%D
    • Profit Margin-0.43%D
    • Gross Margin55.41%B
  • Growth ScoreC
    • Revenue YoY0.32%C
    • Net Profit YoY77.00%A
    • Total Assets YoY2.34%C
    • Net Assets YoY1.63%C
  • Cash ScoreD
    • Cash Flow Margin-23164.65%E
    • OCF YoY0.32%C
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreD
    • Gearing Ratio71.50%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA Grants Accelerated Approval to Bayer’s HYRNUO for Advanced HER2-Mutant Lung Cancer

    The FDA has granted accelerated approval to Bayer's HYRNUO™ (sevabertinib) for treating advanced HER2-mutant lung cancer. This approval is for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations, who have previously received systemic therapy. Sevabertinib is a tyrosine kinase inhibitor, and the approval follows Priority Review and Breakthrough Therapy Designation. Bayer AG announced this on November 20, 2025.

    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%
    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%

    Bayer Wins EU Approval for Lynkuet to Treat Menopausal and Breast Cancer Therapy Hot Flashes

    Bayer AG has received EU approval for Lynkuet™ (elinzanetant), a hormone-free therapy for treating moderate to severe vasomotor symptoms (VMS) like hot flashes associated with menopause or breast cancer therapy. The approval follows positive results from the OASIS Phase III clinical program, showing significant reduction in VMS frequency and severity with a favorable safety profile. Lynkuet™ offers a new treatment option for affected women.

    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%
    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%

    Bayer Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

    Bayer Aktiengesellschaft reported its earnings for Q3 and the first nine months of 2025. Q3 sales were EUR 9,660 million, down from EUR 9,968 million year-over-year, with a net loss of EUR 963 million compared to a loss of EUR 4,183 million last year. For the nine months, sales totaled EUR 34,137 million, slightly down from EUR 34,877 million, but net income improved to EUR 137 million from a loss of EUR 2,217 million. Basic and diluted earnings per share from continuing operations were EUR 0.14, recovering from losses of EUR 2.26 last year.

    marketscreener·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%
    marketscreener·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%

    Bayer Confirms 2025 Financial Outlook Amid Market Challenges

    Bayer AG has confirmed its upgraded financial outlook for 2025, citing strong performance in its agricultural and pharmaceuticals divisions. However, the Consumer Health division faces market challenges, with revised sales growth expectations of minus 1 to plus 1 percent. The company anticipates special items in full-year Group EBITDA to be between minus 4.0 to minus 3.5 billion euros, and in Group EBIT between minus 3.0 to minus 2.5 billion euros, reflecting increased litigation provisions.

    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%
    Reuters·
    US
    BAYZF
    +2.21%
    US
    BAYRY
    +3.39%

    Bayer AG reports Q3 sales of €9.7 billion and net loss of €1.0 billion

    Bayer AG reported Q3 2025 sales of €9.7 billion, a 0.9% increase year-over-year. EBITDA rose 20.8% to €1.5 billion, while core earnings per share increased 137.5% to €0.57. However, the company faced a net loss of €1.0 billion due to litigation charges. Free cash flow fell to €0.6 billion, and net financial debt decreased to €32.7 billion. The Crop Science division performed well, while Pharmaceuticals sales remained stable. Bayer confirmed its outlook and announced Dr. Judith Hartmann will join the Board of Management in 2026.

    Reuters·
    US
    BAYRY
    +3.39%
    US
    BAYZF
    +2.21%
    Reuters·
    US
    BAYRY
    +3.39%
    US
    BAYZF
    +2.21%
    Posts
    View More

    Today, the Qwen app was released, and finally, Alibaba is seriously addressing the 2C market. I immediately conducted a test. I called the most token-consuming DeepReseach to run RXRX, which I current...